{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:04:05Z","timestamp":1792119845213,"version":"4.4.0"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,28]]},"DOI":"10.1097\/qad.0b013e32834bbb90","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T22:15:59Z","timestamp":1317766559000},"page":"2197-2208","source":"Crossref","is-referenced-by-count":31,"title":["Challenges and opportunities for hepatitis C drug development in HIV\u2013hepatitis C virus-co-infected patients"],"prefix":"10.1097","volume":"25","author":[{"given":"Vincent","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210130","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the HIV: the D:A:D study.","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"R3-1-20210130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cld.2010.09.012","article-title":"HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury.","volume":"15","author":"Merwat","year":"2011","journal-title":"Clin Liver Dis"},{"key":"R5-1-20210130","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R6-1-20210130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.","volume":"9","author":"Rockstroh","year":"2008","journal-title":"HIV Med"},{"key":"R7-1-20210130","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"R8-1-20210130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/QAI.0b013e31803151c7","article-title":"Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIVhepatitis C virus-coinfected patients.","volume":"44","author":"Shafran","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-1-20210130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2893.2009.01261.x","article-title":"Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.","volume":"18","author":"Blanco","year":"2011","journal-title":"J Viral Hepat"},{"key":"R10-1-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury.","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"R11-1-20210130","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.","volume":"52","author":"Nunez","year":"2010","journal-title":"Hepatology"},{"key":"R12-1-20210130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","article-title":"Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.","volume":"196","author":"Labarga","year":"2007","journal-title":"J Infect Dis"},{"key":"R13-1-20210130","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/QAD.0b013e328216f2c7","article-title":"Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.","volume":"21","author":"Dore","year":"2007","journal-title":"AIDS"},{"key":"R14-1-20210130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2893.2010.01309.x","article-title":"HCV treatment uptake and changes in the prevalence of HCV genotypes in HIVHCV-coinfected patients.","volume":"18","author":"Medrano","year":"2011","journal-title":"J Viral Hepat"},{"key":"R16-1-20210130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/aid.2005.21.599","article-title":"Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation.","volume":"21","author":"Maida","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R17-1-20210130","first-page":"190","article-title":"Liver and kidney transplantation in HIV-infected patients.","volume":"11","author":"Tan-Tam","year":"2009","journal-title":"AIDS Rev"},{"key":"R18-1-20210130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for hepatitis C virus infection.","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R20-1-20210130","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-1-20210130","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection.","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-1-20210130","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"R23-1-20210130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection.","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-1-20210130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12h with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C.","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"key":"R25-1-20210130","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 HCV (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"R26-1-20210130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"R27-1-20210130","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection.","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-1-20210130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.","volume":"65","author":"Seden","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R29-1-20210130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2011.558839","article-title":"Approaches for understanding and predicting drug interactions in HIV-infected patients.","volume":"7","author":"Jimenez-Nacher","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R30-1-20210130","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIVhepatitis C virus-coinfected patients.","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"key":"R31-1-20210130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiq098","article-title":"Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.","volume":"203","author":"Nattermann","year":"2011","journal-title":"J Infect Dis"},{"key":"R32-1-20210130","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.23489","article-title":"Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.","volume":"51","author":"Petta","year":"2010","journal-title":"Hepatology"},{"key":"R33-1-20210130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2010.08.036","article-title":"Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.","volume":"54","author":"Lange","year":"2011","journal-title":"J Hepatol"},{"key":"R34-1-20210130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAI.0b013e318186ede8","article-title":"Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIVHCV-coinfected patients.","volume":"50","author":"Ryan","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-1-20210130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3851\/IMP1298","article-title":"Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.","volume":"14","author":"Cacoub","year":"2009","journal-title":"Antivir Ther"},{"key":"R37-1-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkn175","article-title":"Why different dynamics of selection of drug resistance in HIV, hepatitis B and C viruses.","volume":"62","author":"Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R38-1-20210130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/QAI.0b013e3181a02fda","article-title":"Detection of hepatitis C mutants with natural resistance to NS34A protease inhibitors in HIVHCV-coinfected individuals treated with antiretroviral therapy.","volume":"51","author":"Morsica","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R40-1-20210130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","article-title":"Viral hepatitis and HIV co-infection.","volume":"85","author":"Soriano","year":"2010","journal-title":"Antivir Res"},{"key":"R41-1-20210130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIVHCV coinfection.","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"R42-1-20210130","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIVHCV coinfection and liver cirrhosis during interferon-based therapy.","volume":"38","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"R43-1-20210130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM200210173471623","article-title":"Weight loss in HIV-infected patients.","volume":"347","author":"Garcia-Benayas","year":"2002","journal-title":"N Engl J Med"},{"key":"R44-1-20210130","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity.","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R45-1-20210130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir Ther"},{"key":"R46-1-20210130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jac\/dkn420","article-title":"Efficacy of pegylated interferon plus ribavirin treatment in HIVhepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.","volume":"62","author":"Mira","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R47-1-20210130","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1097\/QAD.0b013e3283177f38","article-title":"Increase in serum bilirubin in HIVhepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin.","volume":"22","author":"Rodriguez-Novoa","year":"2008","journal-title":"AIDS"},{"key":"R52-1-20210130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterisation of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R55-1-20210130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/QAD.0b013e328344fe96","article-title":"New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B.","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"key":"R56-1-20210130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy.","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"R57-1-20210130","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase HCV RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.","volume":"53","author":"Guedj","year":"2011","journal-title":"Hepatology"},{"key":"R58-1-20210130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus.","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"R59-1-20210130","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"Hepatitis C virus (HCV) and HIV dynamics during HCV treatment in HCVHIV coinfection.","volume":"188","author":"Torriani","year":"2003","journal-title":"J Infect Dis"},{"key":"R60-1-20210130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis Chuman immunodeficiency virus-infected patients.","volume":"128","author":"Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"R61-1-20210130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"R62-1-20210130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2893.2006.00806.x","article-title":"Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCVHIV-coinfected patients.","volume":"14","author":"Ramos","year":"2007","journal-title":"J Viral Hepat"},{"key":"R63-1-20210130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/QAD.0b013e3283471cae","article-title":"IL28B gene polymorphisms and viral kinetics in HIVhepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.","volume":"25","author":"Rallon","year":"2011","journal-title":"AIDS"},{"key":"R64-1-20210130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection.","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"R65-1-20210130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors.","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"R66-1-20210130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkp388","article-title":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).","volume":"65","author":"Kieffer","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R67-1-20210130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of HCV variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects.","volume":"198","author":"Bartels","year":"2008","journal-title":"J Infect Dis"},{"key":"R68-1-20210130","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients.","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"R69-1-20210130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"},{"key":"R71-1-20210130","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive HCV clinical isolates to HCV protease inhibitors.","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R72-1-20210130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1760","article-title":"Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIVHCV-coinfected patients in Spain.","volume":"16","author":"Trevino","year":"2011","journal-title":"Antivir Ther"},{"key":"R73-1-20210130","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1468-1293.2011.00913.x","article-title":"HCV protease variability and anti-HCV protease inhibitor resistance in HIVHCV-coinfected patients.","volume":"12","author":"Trimoulet","year":"2011","journal-title":"HIV Med"},{"key":"R74-1-20210130","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1128\/JCM.01613-10","article-title":"Variability of the polymerase gene (NS5B) in HCV-infected women.","volume":"48","author":"Blackward","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R75-1-20210130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R76-1-20210130","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/hep.24374","article-title":"Distributive justice and the arrival of direct acting antivirals: who should be first in line.","volume":"53","author":"Aronsohn","year":"2001","journal-title":"Hepatology"},{"key":"R78-1-20210130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"R79-1-20210130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1478-3231.2010.02383.x","article-title":"Future hepatitis C virus treatment: interferon-sparing combinations.","volume":"4","author":"Gane","year":"2011","journal-title":"Liver Int"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-201111280-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:08:21Z","timestamp":1712995701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201111280-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,28]]},"references-count":65,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32834bbb90","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,28]]}}}